Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naomaili
- Development stage
- Phase 4
- Lead developer
- Carephar
- Administration
- Oral
01
Overview
Naomaili is a Traditional Chinese Medicine (TCM) formulation approved by the National Medical Products Administration (NMPA) of China in December 2014 for the treatment of ischemic stroke. It is an optimized formula specifically developed for cardio-cerebrovascular diseases and is available as granules. Preclinical studies have demonstrated that Naomaili granules exhibit protective effects against cerebral ischemia and reperfusion injury in animal models, suggesting potential neuroprotective properties relevant to stroke management[1][2][3].
- Brand names
- Naomaili
- Other names
- Naomaili granules
Beyond the preview
Go deeper on naomaili.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naomaili.